Delcath Systems (DCTH)
Commercializing HEPZATO in the United States and CHEMOSAT in Europe for liver-directed oncology.
$16.19
vs last close+0.08 (+0.48%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 50.45% | 17.51M shares | |
|---|---|---|---|
| 129 holders · as of Jun 30, 2026 | |||
| Insiders | 6.83% | 2.37M shares | |
| 5 holders · as of Mar 20, 2026 | |||
| Other | 42.72% | 14.82M shares | |
| remainder | |||
34.70M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
129 holders · 17.51M shares · 21 new positions · 71 increased · 26 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3.30M | 9.51% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 2.71M | 7.80% | +922.3K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.22M | 3.52% | −108.0K | Aug 13, 2026 |
| Propel Bio Management, LLC | 871.5K | 2.51% | −108.2K | Aug 13, 2026 |
| Geode Capital Management, LLC | 733.1K | 2.11% | +41.1K | Aug 12, 2026 |
| State Street Corp | 679.3K | 1.96% | +14.9K | Aug 7, 2026 |
| Algert Global LLC | 580.7K | 1.67% | +435.0K | Aug 13, 2026 |
| Millennium Management LLC | 566.4K | 1.63% | −21.7K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 9.90% | 6.72M | 13D | Feb 10, 2026 |
| BlackRock, Inc. | 5.30% | 1.84M | 13G | Jul 28, 2026 |
| Daniel Kaufman | 5.08% | 1.77M | 13G | Mar 20, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 6, 2026 | Sandra Pennellofficer: Chief Financial Officer | Purchase | 5,533 | $9.04 | 77,018 |
| Mar 2, 2026 | Gerard J. Micheldirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 11,200 | $8.96 | 342,034 |
| Nov 21, 2025 | John Richard Sylvesterdirector | Purchase | 4,386 | $8.89 | 14,936 |
| Nov 11, 2025 | Gerard J. Micheldirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 11,500 | $8.53 | 330,834 |
House and Senate disclosures
Not reported.